QuidelOrtho Corporation (QDEL)

Market Cap	1.81B
Revenue (ttm)	2.74B
Net Income (ttm)	-466.40M
Shares Out	67.90M
EPS (ttm)	-6.92
PE Ratio	n/a
Forward PE	9.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	618,063
Open	25.43
Previous Close	25.19
Day's Range	25.09 - 26.90
52-Week Range	22.05 - 49.45
Beta	-0.03
Analysts	Buy
Price Target	42.57 (+59.44%)
Earnings Date	Aug 5, 2025

About PARAA

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1979
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: QDEL
• Website: https://www.quidelortho.com

Financial Performance

In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for QDEL stock is "Buy." The 12-month stock price target is $42.57, which is an increase of 59.44% from the latest price.

Price Target

$42.57

(59.44% upside)

Analyst Consensus: Buy